News | December 20, 2011

Adult Stem Cell Patients Continue to See Cardiac Improvement Years After Treatment


 

December 20, 2011 –– Howie Lindeman was facing the loss of his career and Neim Malo wasn’t supposed to see 2011. They were each treated for heart disease years ago using their own stem cells to repair their damaged heart tissue. Several years following treatment from Regenocyte, both men continue to see improvement in their condition and quality of life.

Howie Lindeman, 60, had a heart attack at 39 years old that severely damaged his heart. He went through several procedures including having stents placed in his arteries and his physicians were considering open-heart surgery for a quintuple bypass. He was in constant pain and struggled to walk just 25 feet, but when Zannos G. Grekos, M.D., MAAC, FACC, chief medical officer of Regenocyte and a Florida-based pioneer in the field of adult stem cell therapy suggested he have the Regenocyte adult stem cell procedure, he jumped at the opportunity. A normal ejection fraction (EF) is over 50 percent and Lindeman’s was down to a dangerous 22 percent before the adult stem cell procedure. Shortly after receiving treatment, his EF improved to a near-normal 47 percent, and is now at a stable 54 percent.

Neim Malo, 54, suffered a heart attack at 47 years old. He had three stents put in and was told by doctors that he would only live five more years. He refused to accept such a grim fate, so he searched for alternative treatment and found adult stem cell therapy. Malo’s EF was at 28 percent when he received adult stem cell treatment in 2006 and since then, his heart function has improved to 50 percent.

“I have more energy than ever,” said Malo. “You can still find me in my restaurant everyday outpacing people half my age. I’ve lived beyond those five years and will continue to prove my former doctors wrong.”

Lindeman and Malo now participate in Regenocyte seminars to share their experiences with attendees who are considering the treatment for themselves or their loved ones. In his presentation about the Regenocyte procedure, Grekos describes how blood is extracted from the patient and sent on to a laboratory where the patient’s stem cells are removed.

“The lab provides a key step in the Regenocyte process,” Grekos explained. “The lab extracts the stem cells from the blood and activates them into millions of adult stem cells while ‘educating’ them to assist the exact organ that needs treatment.”

About a week after the blood arrives at the laboratory, the adult stem cells are shipped to a hospital at an international location and the patient has already been admitted.

In this groundbreaking treatment, cardiologist inserted a catheter into Lindeman and Malo’s hearts. Over the next 20 minutes, about 30 separate injections of adult stem cells were introduced into the damaged part of their hearts. The process of tissue repair began almost immediately.

Patients remain in the hospital overnight for observation, and are typically discharged the next day. Grekos continues to have regular appointments with patients to monitor their progress and measure their results.

“We continue to see remarkable results from adult stem cell treatment,” said Grekos. “Successes like those we’ve seen with Howie and Neim are not uncommon and show significant promise for diseases in other organs.”

“I have a high-stress, high-energy job that I absolutely love,” says Lindeman. “The Regenocyte adult stem cell treatment has allowed me to continue my career and enjoy the active lifestyle I thought I had lost for good. I’m a new person and I continue to feel better every day.”

Grekos and the Regenocyte medical team continue to research the impact of adult stem cell therapy on heart disease.

For more information: www.regenocyte.com


Related Content

News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Subscribe Now